Get the Stockscreener App
0.9631
5.58%
-0.0569
After Hours:
1.00
0.0369
+3.83%
Fate Therapeutics Inc stock is traded at $0.9631, with a volume of 1.44M.
It is down -5.58% in the last 24 hours and up +2.86% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.02
Open:
$1.02
24h Volume:
1.44M
Relative Volume:
0.90
Market Cap:
$111.07M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.5837
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
-4.64%
1M Performance:
+2.86%
6M Performance:
-4.64%
1Y Performance:
-74.25%
1-Day Range:
$0.9601
$1.02
1-Week Range:
$0.9335
$1.08
52-Week Range:
$0.6611
$4.20
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
0.9631 | 115.33M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Nuveen LLC Purchases Shares of 379,088 Fate Therapeutics, Inc. $FATE - MarketBeat
Walleye Capital LLC Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Leerink Partnrs Analysts Raise Earnings Estimates for FATE - MarketBeat
Will Fate Therapeutics Inc. outperform small cap indexesJuly 2025 Chart Watch & Comprehensive Market Scan Reports - Lancaster City Council
RSI + MACD Show Convergence for Fate Therapeutics Inc.2025 Dividend Review & Weekly Stock Breakout Alerts - beatles.ru
Analysts Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $3.30 - MarketBeat
Price Floor Holding on Fate Therapeutics Inc. — Rebound PossibleJuly 2025 Summary & Verified Short-Term Trading Plans - beatles.ru
Using data models to predict Fate Therapeutics Inc. stock movementEarnings Recap Summary & Consistent Return Investment Signals - Newser
Volume spikes in Fate Therapeutics Inc. stock – what they meanGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser
Heatmap analysis for Fate Therapeutics Inc. and competitorsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - Newser
Visual trend scoring systems applied to Fate Therapeutics Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser
What MACD and RSI say about Fate Therapeutics Inc.July 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
Leerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE) - The Globe and Mail
Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace
Can technical indicators confirm Fate Therapeutics Inc.’s reversalSwing Trade & Stock Market Timing Techniques - Newser
What are analysts’ price targets for Fate Therapeutics Inc.2025 Market Overview & Smart Swing Trading Alerts - خودرو بانک
Key metrics from Fate Therapeutics Inc.’s quarterly dataEarnings Recap Summary & Safe Investment Capital Preservation Plans - Newser
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Does Fate Therapeutics Inc. show high probability of rebound2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
Detecting support and resistance levels for Fate Therapeutics Inc.Weekly Stock Recap & Target Return Focused Picks - Newser
Can volume confirm reversal in Fate Therapeutics Inc.2025 Fundamental Recap & Technical Buy Zone Confirmation - Newser
Leerink Partners Maintains Fate Therapeutics(FATE.US) With Buy Rating, Cuts Target Price to $7 - 富途牛牛
Institutional scanner results for Fate Therapeutics Inc.Trade Volume Summary & Growth Focused Entry Point Reports - Newser
Will Fate Therapeutics Inc. bounce back from current supportPortfolio Risk Report & Weekly High Conviction Trade Ideas - Newser
Is Fate Therapeutics Inc. trending in predictive chart modelsWeekly Trade Recap & Real-Time Stock Movement Alerts - Newser
Can machine learning forecast Fate Therapeutics Inc. recoveryPrice Action & Stock Market Timing Techniques - Newser
Fate Therapeutics' Equity Incentive Strategy and Its Implications for Talent Retention and Long-Term Value Creation - AInvest
Fate Therapeutics shares rise 3% after-hours following new employee inducement grants. - AInvest
Is Fate Therapeutics Inc. stock entering bullish territoryTrade Exit Summary & Weekly High Potential Alerts - Newser
Leerink Partners lowers Fate Therapeutics stock price target to $7 on iPSC CAR’iT pivot - Investing.com Canada
Does Fate Therapeutics Inc. align with a passive investing strategyInflation Watch & Consistent Income Trade Recommendations - خودرو بانک
What are Fate Therapeutics Inc.’s recent SEC filings showingQuarterly Profit Review & Breakout Confirmation Trade Signals - خودرو بانک
Why Fate Therapeutics Inc. stock attracts strong analyst attentionTrade Analysis Summary & Short-Term Trading Alerts - Newser
Published on: 2025-09-03 09:36:15 - Newser
Has Fate Therapeutics Inc. found a price floorWall Street Watch & Risk Managed Trade Strategies - Newser
Will Fate Therapeutics Inc. stock hit new highs in YEARGap Down & Verified Swing Trading Watchlist - خودرو بانک
Chart overlay techniques for tracking Fate Therapeutics Inc.2025 Technical Patterns & Entry and Exit Point Strategies - Newser
Building trade automation scripts for Fate Therapeutics Inc.M&A Rumor & Low Risk Entry Point Tips - Newser
Is Abeona Therapeutics Inc. attractive at current valuationTrade Performance Summary & Community Trade Idea Sharing - خودرو بانک
Backtesting results for Fate Therapeutics Inc. trading strategiesMarket Trend Review & Smart Allocation Stock Reports - Newser
Market reaction to Fate Therapeutics Inc.’s recent newsJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
What is Fate Therapeutics Inc. s 5 year growth outlookTrade Volume Report & Weekly Breakout Stock Alerts - خودرو بانک
Is Fate Therapeutics Inc. forming a bottoming baseJuly 2025 Sector Moves & Stock Portfolio Risk Management - Newser
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):